drugset / Trial / NCT01460069

The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis

NCT01460069

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to investigate the effect of the GLP-1 analogue Victoza® on psoriasis in a double-blinded, randomized placebo-controlled clinical trial.

Timeline

Start
2011-10
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 1.8 mg Subcutaneous

Indications